Topics:

New Epothilone KOS-1803 Optimizes Tumor Penetration

New Epothilone KOS-1803 Optimizes Tumor Penetration

LOS ANGELES—The third-generation epothilone KOS-1803 may optimize tumor penetration while limiting exposure to other tissues, researchers reported at the 2007 American Association for Cancer Research annual meeting (abstract 1438). KOS-1803 is a potent microtubule stabilizer. Compared with other epothilones, investigators maintain that it has higher drug accumulation in the tumor and a larger volume of distribution, including large tumor-to-brain ratio and long elimination half-life.

Ziyang Zhong, PhD, and colleagues at Kosan Biosciences, Hayward, California, conducted the research in collaboration with Memorial Sloan-Kettering Cancer Center investigators.

Dr. Zhong reported significant tumor regression with KOS-1083 in multiple mouse xenograft models, including breast, ovarian, lung, prostate, colorectal, and neuroblastoma. In a taxane-insensitive breast xenograft model, KOS-1803 in low doses suppressed tumor growth by nearly 100%. In ovarian carcinoma-bearing mice, KOS-1803, given at 15 mg/kg every 6 days for five doses, achieved a total cure of the cancer without relapse in all mice.

Excellent antitumor activity was also shown in a neuroblastoma mouse model, in which 50% of mice treated with the compound were cured. In various other tumor models, KOS-1803 demonstrated clear anti-tumor activity at low dosing intensity and infrequent dosing (every 6 to 7 days or every 12 days), Dr. Zhong said. Tolerability was good, with GI disturbance the most common toxicity and no evidence of neurotoxicity.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.